Skip to main content

Table 2 Clinical characteristics at baseline and after three and six treatments with erenumab for the patients who presented with medication overuse (MOH) and non-medication overuse (nMOH) at baseline, before treatment initiation

From: A prospective real-world analysis of erenumab in refractory chronic migraine

 BaselineMonth 3Month 6
MOHnMOHMOHnMOHMOHnMOH
Migraine days19.0 ± 0.919.9 ± 1.212.4 ± 1.2*14.7 ± 1.811.4 ± 1.3*13.3 ± 2.2#
P = 0.2P = 0. 1P = 0. 1
Headache Days23.2 ± 0.723.8 ± 0.815.3 ± 1.3*19.5 ± 1.6#15.7 ± 1.4*18.2 ± 2.0
P = 0.3P = 0.1P = 0. 1
Crystal clear headache days4.6 ± 0.62.7 ± 0.69.4 ± 1.2*5.7 ± 1.4#8.2 ± 1.4*4.5 ± 1.5
P = 0.1P = 0.3P = 0. 1
Days consumed abortives17.9 ± 0.74.0 ± 0.410.3 ± 1.0*4.4 ± 0.69.7 ± 1.1*3.8 ± 0.7
P < 0.001P = 0.1P = 0. 001
HIT-666.7 ± 1.066.7 ± 1.058.3 ± 1.3*60.2 ± 2.2#53.4 ± 3.1*62.1 ± 4.3
P = 0.8P = 0.2P = 0. 4
  1. *P < 0.05 compared to baseline values in MOH patients
  2. # P < 0.05 compared to baseline values in nMOH patients
\